Rationale: Pulmonary complications of sickle cell anemia (Hb-SS) commonly cause morbidity, yet few large studies of pulmonary function tests (PFTs) 
Introduction:
Sickle cell anemia (Hb-SS) results from homozygosity for a point mutation in the β-globin gene (HBB; glu6val) causing the resultant sickle hemoglobin (Hb-S) to be less soluble when deoxygenated than normal hemoglobin (1) . Even with improved treatment, including the early use of prophylactic antibiotic regimens, judicious transfusions and the administration of hydroxyurea in selected patients, mortality remains high for this population. The median age at death is 42 years for males and 48 years for females with Hb-SS. Pulmonary complications, including acute chest syndrome (ACS), pulmonary hypertension (PH), and pulmonary fibrosis, account for 20-30% of deaths in the Hb-SS population and are often under-recognized by the health care community (2, 3) .
Dyspnea is a frequent complaint amongst patients with sickle cell disease, the etiology of which is unclear and likely multi-factorial (4, 5) . Studies of lung function to date in this population have been of modest size, often involving less than 50 patients (4, (6) (7) (8) (9) (10) (11) and largely inconclusive. Their results have yielded a spectrum of abnormalities including restrictive lung disease, abnormal diffusion capacity for carbon monoxide (D L CO), obstructive disease and hypoxemia (4, 6, 7, 9, 12) . No definitive profile for pulmonary function in sickle cell disease has emerged. As a result, clinicians find pulmonary function tests (PFTs) difficult to interpret in this population and their clinical utility for directing further investigation and therapy has not been well evaluated.
Of growing concern is the link between obstructive lung disease and ACS, particularly in children (7, 13, 14) . The few published studies suggest that obstructive lung disease, in some cases, plays a role in the pathogenesis of ACS (7, 13, 15) . Moreover, obstructive lung disease could be a long-term sequelae of recurrent episodes of ACS (6, 9) . Larger scale studies are necessary to elucidate more clearly the interaction between lung function and ACS. Additionally, certain findings on PFTs might be a marker of other complications of sickle vasculopathy. For example, an isolated decreased D L CO is a well-established finding associated with PH (16, 17) . However, its role as a marker or predictor of PH in the Hb-SS population is unknown. The purpose of this study is to evaluate the relation of the demographic, clinical and laboratory characteristics to lung function in the SCD population. PFTs were done on subjects recruited as part of the Cooperative Study of Sickle Cell Disease (CSSCD), a cross-sectional epidemiological study. Some of the results of these studies have been previously presented in the form of an abstract at the 47 th annual meeting of the American Society of Hematology (18) .
Methods:
Patient Database: PFTs were collected as part of the CSSCD which enrolled and followed over 4,000 patients with SCD evaluated at one of 23 participating clinical centers across the United States between 1978 and 1998 (19, 20) . One of the primary goals of the CSSCD was to collect data on the clinical course of SCD from birth to death. From the original study population, only the 2061 (51%) subjects with sickle cell anemia were included in this study. The study population was further limited by inclusion of only those subjects who were African-American and over the age of 18 years. A history of acute chest syndrome (ACS) was assessed as part of the original data collection. ACS was defined as a) a new infiltrate on chest radiograph or b)
pleuritic chest pain and/or dyspnea in addition to an abnormal ventilation-perfusion scan. As part of the standard protocol established by the CSSCD, each subject underwent pulmonary function testing three times to ensure reproducibility. If the results from the three studies differed by more than 2%, the study was considered to be of poor quality. Prior to entering into the database, all PFTs were reviewed for quality by pulmonologists at either Harlem Hospital in New York, NY or Howard University
Medical Center in Washington, DC as part of the standard protocol. Upon our review of the data, we considered data insufficient if the evaluation was considered poor quality or if more than 25% of the data for a subject was missing, suggesting an inability to perform the tests correctly; these cases were subsequently removed from our database.
Review of these data was approved by the Institutional Review Board of Boston University/Boston Medical Center. Analysis of variance (ANOVA) was used to calculate both the unadjusted and ageadjusted means for each laboratory measure and these means were compared using an F test (SAS software version 8.2).
Results:
Patient Characteristics (Table 1) : 310 adult subjects were eligible for this study after subjects who were not African American, homozygous for HbS and those without complete PFTs were excluded. The average age of the subjects was 30.7 ±10.3 years (range 20-67 years) and 41% were males. Subjects had a normal body habitus as reflected by a body mass index of 21.3 ± 4.2. ACS was common in this population, with 37% of subjects reporting a history of ACS prior to enrollment in the study and an additional 38% reported an incident episode during the follow-up period.
Laboratory Values (Table 1 assessed by serum creatinine concentrations were within normal laboratory ranges in this population; however, creatinine is now known to be an insensitive measure of glomerular filtration rate in Hb-SS (27) . The patterns of pulmonary function abnormalities observed in those with a history of ACS were similar to those without a history of ACS with restrictive disease and an abnormal diffusion capacity predominating. (Figure 1 ): As our population did not have a predominance of obstructive disease as observed in other studies of the pediatric population (7, (13) (14) (15) , we evaluated the effects of age on TLC and D L CO.
Pulmonary Function in Hb-SS Patients (

Decreased D L CO is Associated with Increasing Age
Interestingly, a negative linear correlation existed between D L CO and age suggesting that in Hb-SS adults, disruption of alveolar-capillary gas exchange may be a potential mechanism for hypoxemia in older Hb-SS adults. There was no association between TLC and age in this population (data not shown). The most common PFT abnormality observed was restrictive disease. According to the ATS guidelines, the best diagnostic test for the presence of restrictive disease is a TLC < 80% predicted (25) . When we examined the group of patients with restrictive disease, an interesting pattern emerged. Of the 230 subjects with restrictive disease, only 111 (48.3%) had the full constellation of low TLC, abnormal spirometry (reduced FEV 1 and FVC, with a FEV 1 /FVC > 70%) and reduced D L CO. The remaining subjects were characterized by low lung volumes with normal spirometry. The categorization of these subjects together reflects the fact that a low TLC alone is enough to make a diagnosis of restriction (25) . Our population demonstrates a divergence of spirometry and lung volumes contradicting other studies in the literature. Previously, in a large-scale study of a healthy Caucasian population, only 2.4% of subjects with a normal FVC had restrictive disease and it was recommended that spirometry alone was sufficient to exclude the presence of restriction unless a high degree of clinical suspicion was present (29) . In Hb-SS, it appears clear that spirometry alone is not sufficient to predict the presence of restrictive lung disease.
Association of Restrictive Lung Disease with Severity of Hb-SS (
One explanation for this may be racial differences inherent to the sickle cell population.
Race is an important determinant of lung function. Previous studies have demonstrated
that, on average, equations for predicted values of PFT data based upon data generated in Caucasians over-estimate the TLC, FEV 1 , and FVC by 12% and the RV and functional residual capacity (FRC) by 7% (25) . Although all of our data were corrected for race prior to analysis, there may still be a differential pattern present.
Another possible explanation may stem from extra-pulmonary causes of restrictive physiology. In the Hb-SS population, one extra-pulmonary mechanism of restriction would be ineffective inspiration due to chest wall pain related to peripheral vasoocclusion, prior rib infarctions or vertebral disease (30) . Although the PFTs obtained in this study were done while the subjects were clinically at their baseline, even when clinically well, Hb-SS patients may have sub-acute vasoocclusion (31) . The amount of chest wall discomfort experienced by the subjects at the time of their testing is unknown but could have contributed to the low lung volumes observed. Additionally, there may be differences in chest wall and vertebral structure among adults with Hb-SS contributing to the restrictive physiology. This could be due to repeated bony infarctions during growth and development and the spinal osteoporosis and osteomalacia typical of Hb-SS (32-34). Non-SCD specific etiologies of extra-pulmonary restriction such as obesity may be playing a role in the restrictive physiology observed in a subset of the subjects observed. The presence of restrictive physiology was associated with a trend towards more severe clinical disease, as exemplified by lower total hemoglobin concentrations and hematocrits, leukocytosis and renal dysfunction (elevated BUN and creatinine) ( Table 4 ). The association of leukocytosis with a decrease in the TLC supports the notion that restrictive lung disease occurs as a result of repeated episodes of ACS and may be a risk factor for mortality (2) . The occurrence of more frequent episodes of ACS may be a risk factor for the development of pulmonary fibrosis, a common etiology of restrictive physiology on PFTs. Additionally, this suggests that the patients with restrictive lung disease have a greater propensity towards vasoocclusion placing them at increased risk for the development of bony infarcts. Interestingly, we noted an association between chronic organ dysfunction of the lungs and the kidneys in our population, confirming findings of prior studies and suggesting an etiologic link between these two entities (35) .
An equally interesting finding is the presence of a decreased D L CO in Hb-SS adults. In 13% of subjects, this was the only PFT abnormality observed. An isolated decreased D L CO can be a marker for early interstitial lung disease (36) or more commonly, is associated with the presence of PH. In patients with systemic sclerosis, a D L CO <55% predicted may be observed in patients up to 5 years prior to the diagnosis of PH and is thought to be an early screening tool in this population (17, 37) . Moreover, in patients with idiopathic pulmonary arterial hypertension (IPAH), a low D L CO is not only a marker of PH, but is also an independent predictor of mortality (16) . Unfortunately, as the CSSCD was designed prior to the determination of the importance of PH in the natural history of SCD, echocardiographic data is not available on the majority of the study subjects. Because of this, a definitive conclusion about the relationship between a reduced D L CO and the presence of PH cannot be made. We recognize that this is a shortcoming of the current study and recommend a longitudinal study evaluating pulmonary function tests and echocardiograms in Hb-SS adults to clarify this issue.
Age-adjusted multivariate analysis revealed a link between the presence of a low D L CO with markers of hepatic and renal dysfunction and with thrombocytosis. Prior studies of PH in Hb-SS have revealed an association of PH with a history of renal dysfunction and an elevation in ALT (28, 38) . Additionally, platelets appear to have an important role pathogenically in the development of PH both as mediators of serotonin metabolism and in their role in thrombosis. These observations support the notion that a decreased D L CO may be associated with PH in the SCD population. Unfortunately, the lack of correlative echocardiographic data limits our ability to draw definitive conclusions about the link between a decreased D L CO and PH in this population.
Limitations of the current analysis stem from the study design. As this was a crosssectional study of pulmonary function data, it is impossible to assess the longitudinal effects of Hb-SS disease on pulmonary function. The lack of a non-SCD control group also limits the interpretability of this study somewhat. It would be interesting to determine if the apparent obstructive disease observed in the pediatric Hb-SS population undergoes a transition to a more restrictive pattern in adulthood.
Additionally, testing for airway hyperreactivity, such as response to inhaled bronchodilators or methacholine challenge testing was not done. In conclusion, pulmonary function is abnormal in 90% of adults with Hb-SS. It is likely that abnormal pulmonary function reflects intrinsic lung disease in these patients and that the mechanisms of dyspnea are more complex in this population than originally appreciated. Greater understanding of the diagnostic utility of pulmonary function testing in this population is paramount as it could lead to a more comprehensive appraisal of the mechanisms responsible for dyspnea and hypoxemia. 
